欢迎访问《现代生物医学进展》编辑部！

目的：研究降纤酶治疗急性脑梗塞的疗效以及对血浆纤维蛋白原的影响。方法：选取2010 年4 月到2014 年6 月我院收治的急性脑梗塞患者130 例，按照随机数字表法将患者分为研究组和对照组，每组65 例，两组均给予常规治疗，对照组在常规治疗的基础上给予安慰剂，研究组给予降纤酶，比较两组临床疗效、神经功能缺损评分、血浆纤维蛋白原水平以及不良反应。结果：研究组总有效率为95.4％，显著高于对照组的76.9％（P＜0.05）；治疗后研究组神经功能缺损评分与治疗前和对照组比较差异具有统计学意义（P＜0.05）；治疗后研究组血浆纤维蛋白原显著低于治疗前和对照组（P＜0.05）；两组不良反应比较差异无统计学意义（P>0.05）。结论：降纤酶治疗急性脑梗塞具有较好的临床疗效，改善患者的神经功能，降低血浆纤维蛋白原。

英文摘要:

Objective:To study the efficacy of defibrase in treatment of acute cerebral infarction(ACI) and its influence on plasma fibrinogen.Methods:A total of 130 patients with ACI, who were admitted to Guangyuan Central Hospital from April 2010 to June 2014, were selected and randomly divided into study group(n=65) and control group(n=65). The patients of two groups were treated with conventional therapy, on the basis of which, the control group was added placebo, while the study group, defibrase. Then the efficacy, neural function defect score, plasma fibrinogen levels and adverse reactions in the two groups were compared.Results:The total efficiency (95.4％) in the study group was significantly higher than that (76.9％) in the control group (P<0.05). The neural function defect score in the study group after treatment has a significant difference compared with before treatment and the control group (P<0.05). The plasma fibrinogen level in the study group after treatment was significantly lower than before treatment and the control group(P<0.05). There was no statistical significance in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Defibrase has a better efficacy in the treatment of patients with acute cerebral infarction,which can improve the neural function and reduce plasma fibrinogen levels of patients with ACI.

View Full Text View/Add Comment Download reader